Zsolt Harsanyi Sells 7,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock
Emergent Biosolutions, Inc. (NYSE:EBS) Director Zsolt Harsanyi sold 7,000 shares of Emergent Biosolutions stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the completion of the transaction, the director now directly owns 37,077 shares in the company, valued at $1,574,660.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Emergent Biosolutions, Inc. (NYSE:EBS) opened at $45.48 on Wednesday. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1,826.36, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 1.22 and a beta of 1.24. Emergent Biosolutions, Inc. has a 1 year low of $27.94 and a 1 year high of $45.81.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. The business had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.56 EPS. equities research analysts predict that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current year.
Institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its holdings in shares of Emergent Biosolutions by 47.2% during the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after buying an additional 290,863 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Emergent Biosolutions by 7.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after buying an additional 152,029 shares in the last quarter. Peregrine Capital Management LLC boosted its holdings in shares of Emergent Biosolutions by 40.8% during the 3rd quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock valued at $18,399,000 after buying an additional 131,692 shares in the last quarter. Aberdeen Asset Management PLC UK boosted its holdings in shares of Emergent Biosolutions by 7.3% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock valued at $58,918,000 after buying an additional 118,894 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Emergent Biosolutions by 16.7% during the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after buying an additional 117,700 shares in the last quarter. 92.70% of the stock is currently owned by institutional investors and hedge funds.
EBS has been the topic of several analyst reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective on the stock in a research report on Tuesday, November 28th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $46.00.
ILLEGAL ACTIVITY WARNING: “Zsolt Harsanyi Sells 7,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/zsolt-harsanyi-sells-7000-shares-of-emergent-biosolutions-inc-ebs-stock/1760610.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with Analyst Ratings Network's FREE daily email newsletter.